Syphilis Negatively Influences the Response to Hepatitis C Virus Treatment in an HIV-infected Patient

Overview

Journal Top Antivir Med

Specialties Infectious Diseases
Microbiology

Date 2012 Nov 17

PMID 23154253

Authors

Ellen H Nagami

Arthur Y Kim

Rachel P Baden

Barbara H McGovern

Affiliations

Soon will be listed here.

References

Salazar J, Cruz A, Pope C, Valderrama L, Trujillo R, Saravia N . Treponema pallidum elicits innate and adaptive cellular immune responses in skin and blood during secondary syphilis: a flow-cytometric analysis. J Infect Dis. 2007; 195(6):879-87. PMC: 2131710. DOI: 10.1086/511822. View

Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y . Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology. 2010; 139(2):499-509. DOI: 10.1053/j.gastro.2010.04.049. View

Ferenci P, Laferl H, Scherzer T, Gschwantler M, Maieron A, Brunner H . Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology. 2008; 135(2):451-8. DOI: 10.1053/j.gastro.2008.04.015. View

Dill M, Duong F, Vogt J, Bibert S, Bochud P, Terracciano L . Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology. 2010; 140(3):1021-31. DOI: 10.1053/j.gastro.2010.11.039. View

Saludes V, Bracho M, Valero O, Ardevol M, Planas R, Gonzalez-Candelas F . Baseline prediction of combination therapy outcome in hepatitis C virus 1b infected patients by discriminant analysis using viral and host factors. PLoS One. 2010; 5(11):e14132. PMC: 2994723. DOI: 10.1371/journal.pone.0014132. View

Jacobson I, McHutchison J, Dusheiko G, Di Bisceglie A, Reddy K, Bzowej N . Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364(25):2405-16. DOI: 10.1056/NEJMoa1012912. View

Nasta P, Gatti F, Puoti M, Cologni G, Bergamaschi V, Borghi F . Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a. AIDS. 2008; 22(7):857-61. DOI: 10.1097/QAD.0b013e3282fbd1c4. View

Darling J, Aerssens J, Fanning G, McHutchison J, Goldstein D, Thompson A . Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology. 2011; 53(1):14-22. PMC: 3083026. DOI: 10.1002/hep.24056. View

Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A . Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004; 292(23):2839-48. DOI: 10.1001/jama.292.23.2839. View

10.

Sarasin-Filipowicz M, Oakeley E, Duong F, Christen V, Terracciano L, Filipowicz W . Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A. 2008; 105(19):7034-9. PMC: 2383932. DOI: 10.1073/pnas.0707882105. View

11.

Sellati T, Wilkinson D, Sheffield J, Koup R, Radolf J, Norgard M . Virulent Treponema pallidum, lipoprotein, and synthetic lipopeptides induce CCR5 on human monocytes and enhance their susceptibility to infection by human immunodeficiency virus type 1. J Infect Dis. 1999; 181(1):283-93. DOI: 10.1086/315209. View

12.

Thurnheer M, Weber R, Toutous-Trellu L, Cavassini M, Elzi L, Schmid P . Occurrence, risk factors, diagnosis and treatment of syphilis in the prospective observational Swiss HIV Cohort Study. AIDS. 2010; 24(12):1907-16. DOI: 10.1097/QAD.0b013e32833bfe21. View

13.

Zeremski M, Markatou M, Brown Q, Dorante G, Cunningham-Rundles S, Talal A . Interferon gamma-inducible protein 10: a predictive marker of successful treatment response in hepatitis C virus/HIV-coinfected patients. J Acquir Immune Defic Syndr. 2007; 45(3):262-8. DOI: 10.1097/QAI.0b013e3180559219. View

14.

Sherman K, Flamm S, Afdhal N, Nelson D, Sulkowski M, Everson G . Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011; 365(11):1014-24. PMC: 3809077. DOI: 10.1056/NEJMoa1014463. View

15.

Martin-Carbonero L, Nunez M, Marino A, Alcocer F, Bonet L, Garcia-Samaniego J . Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. AIDS. 2007; 22(1):15-21. DOI: 10.1097/QAD.0b013e3282f1da99. View

16.

Jensen D, Marcellin P, Freilich B, Andreone P, Di Bisceglie A, Brandao-Mello C . Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med. 2009; 150(8):528-40. DOI: 10.7326/0003-4819-150-8-200904210-00007. View

17.

Knudsen A, Benfield T, Kofoed K . Cytokine expression during syphilis infection in HIV-1-infected individuals. Sex Transm Dis. 2009; 36(5):300-4. DOI: 10.1097/OLQ.0b013e318193ca26. View

18.

Jensen D, Morgan T, Marcellin P, Pockros P, Reddy K, Hadziyannis S . Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology. 2006; 43(5):954-60. DOI: 10.1002/hep.21159. View

19.

Yoneda S, Umemura T, Katsuyama Y, Kamijo A, Joshita S, Komatsu M . Association of serum cytokine levels with treatment response to pegylated interferon and ribavirin therapy in genotype 1 chronic hepatitis C patients. J Infect Dis. 2011; 203(8):1087-95. DOI: 10.1093/infdis/jiq165. View

20.

. Syphilis on the rise in the USA. Lancet. 2011; 378(9791):542. DOI: 10.1016/S0140-6736(11)61274-9. View